Asset Details
Do you wish to reserve the book?
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer
Do you wish to request the book?
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer
2022
Overview
Resistance to EGFR inhibitors (EGFRi) presents a major obstacle in treating non-small cell lung cancer (NSCLC). One of the most exciting new ways to find potential resistance markers involves running functional genetic screens, such as CRISPR, followed by manual triage of significantly enriched genes. This triage process to identify ‘high value’ hits resulting from the CRISPR screen involves manual curation that requires specialized knowledge and can take even experts several months to comprehensively complete. To find key drivers of resistance faster we build a recommendation system on top of a heterogeneous biomedical knowledge graph integrating pre-clinical, clinical, and literature evidence. The recommender system ranks genes based on trade-offs between diverse types of evidence linking them to potential mechanisms of EGFRi resistance. This unbiased approach identifies 57 resistance markers from >3,000 genes, reducing hit identification time from months to minutes. In addition to reproducing known resistance markers, our method identifies previously unexplored resistance mechanisms that we prospectively validate.
Resistance to EGFR inhibitors presents a major obstacle in treating non-small cell lung cancer. Here, the authors develop a recommender system ranking genes based on trade-offs between diverse types of evidence linking them to potential mechanisms of EGFRi resistance.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Barriers
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ CRISPR
/ Drug Resistance, Neoplasm - genetics
/ Epidermal growth factor receptors
/ Genes
/ Humanities and Social Sciences
/ Humans
/ Lung Neoplasms - drug therapy
/ Markers
/ Mutation
/ Non-small cell lung carcinoma
/ Pattern Recognition, Automated
/ Protein Kinase Inhibitors - pharmacology
/ Science
